HCRN-GU23-651

A Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Currently Enrolling

All sites in which the trial HCRN-GU23-651 being conducted in.